

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zeldis <i>et al.</i>	Confirmation No.:	7262
Patent No.:	7,435,726	Art Unit:	1623
Serial No.:	09/853,617		
Filed:	May 14, 2001	Examiner:	Dr. Patrick T. Lewis
For:	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER	Attorney Docket No:	501872-999021
		CAM:	9516-022-999

**REQUEST FOR RECONSIDERATION OF
PATENT TERM ADJUSTMENT UNDER 37 C.F.R. § 1.705(d)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees respectfully request reconsideration of the Determination of Patent Term Adjustment under 35 U.S.C. §154(b) ("Determination") stated on the Issue Notification of September 24, 2008 in connection with the above-referenced patent. It is alleged in the Determination that the patent term adjustment is 117 days. Patentees respectfully disagree. As set forth below, the correct patent term adjustment is 612 days.

I. The Instant Request is Proper and Timely Filed

The instant patent issued October 14, 2008, *i.e.*, less than two months prior to the instant Request. Further, this Request is being filed in light of, *inter alia*, *Wyeth v. Dudas*, 2008 WL 4445642, 88 U.S.P.Q.2d 1538 (D.D.C. 2008). *Wyeth* was decided on September 30, 2008, which is after the date in which the issue fee was paid for the instant patent, *i.e.*, after August 13, 2008. Thus, this Request is proper and timely. *See* 37 C.F.R. §1.705(d).

II. Calculation of Patent Term Adjustment

A. PTO Delays Under 35 U.S.C. §154(b)(1)(A)

1. Failure to issue an Action under 35 U.S.C. §132 within 14 months of filing date

A patentee is entitled to a patent term adjustment equal to the number of days “in the period beginning on the day after the date that is fourteen months after the date on which the application was filed...and ending on the date of mailing of...an action under 35 U.S.C. §132....” 37 C.F.R. §1.703(a)(1); *see also* 35 U.S.C. 154(b)(1)(A)(i). The filing date of the instant patent is May 14, 2001. Thus, a first action was due July 15, 2002, *i.e.*, fourteen months after the date of filing. A Restriction Requirement was not mailed until December 3, 2002. Thus, the period of Office delay for failure to issue an action within 14 months is 142 days.

2. Failure to respond to a reply under 37 C.F.R. §1.111 within 4 months of Patentees’ reply

A patentee is entitled to a patent term adjustment equal to the number of days “in the period beginning on the day after the date that is four months after the date of reply under §1.111 was filed and ending on the date of mailing of...an action under 35 U.S.C. §132....” 37 C.F.R. §1.703(a)(2); *see also* 35 U.S.C. §154(b)(1)(A)(ii).

Patentees respectfully invite the Office’s attention to the Patent Term Adjustment History¹ (“History”) obtained from the Patent Application Information Retrieval (“PAIR”) of the United States Patent and Trademark Office (“USPTO”) website. According to the History, a Non-Final Rejection was mailed May 19, 2003. However, contrary to what is described in the History, a Response to this Non-Final Rejection was not mailed on March 12, 2004. Rather, a Response was timely filed on August 19, 2003, *i.e.*, within three-months of the date of mailing of the Non-Final Rejection of May 19, 2003.² This is evidenced by: (1)

¹ Attached hereto as Exhibit A.

² Considering the date of the Office Action was May 19, 2003, this application would have been abandoned if a response was not filed until March 12, 2004. No notice of abandonment issued, evidencing the fact that a response could not have been filed on March 12, 2004.

a copy of the Response as filed³, which is dated August 19, 2003; and (2) a copy of the Express Mail Receipt submitted concurrently with the Response⁴, which bears a USPTO stamp having the date August 19, 2003. The Express Mail receipt is also indexed on PAIR under the "Image File Wrapper" as a "Miscellaneous Incoming Letter" for the date of August 19, 2003.

It appears that a second copy of the Response filed August 19, 2003 was faxed to the USPTO on March 12, 2004, presumably upon request by the Examiner. (*See, e.g.*, Exhibit E⁵). In this regard, patentees respectfully submit that the Office has mistakenly considered the date of March 12, 2004, rather than the correct date of August 19, 2003, to be the filing date of the Response. Moreover, the Office has improperly deducted 206 days resulting from this error.⁶

Following the Response filed August 19, 2003, a subsequent Final Rejection was not mailed from by the Office until April 20, 2005. As discussed above, a patentee is entitled to a patent term adjustment equal to "[t]he number of days...in the period beginning on the day after the date that is four months after the date a reply in compliance with §1.111 was filed and ending on the date of mailing of...an action under 35 U.S.C. 132...." Since Patentees' Response was filed August 19, 2003, an action was due December 19, 2003. The subsequent Final Rejection was not mailed until April 20, 2005. Thus, period of Office delay for the failure to mail an action within four months is 488 days, rather than the 282 days indicated in the History.⁷

³ Attached hereto as Exhibit B. The Response is also indexed in the "Image File Wrapper" on PAIR, attached hereto as Exhibit C. The electronic copy of the Response found in the "Image File Wrapper" on PAIR is dated August 19, 2003.

⁴ Attached hereto as Exhibit D.

⁵ A copy is also indexed as a "Transmittal to TC" for the date of March 12, 2004 in the "Index File Wrapper" of PAIR.

⁶ This PTO error was also brought to the Office's attention in Patentees' Request for Reconsideration of Patent Term Adjustment Under 37 C.F.R. §1.705(b) filed August 13, 2008.

⁷ In Patentees' Request for Reconsideration of Patent Term Adjustment Under 37 C.F.R. §1.708(b) filed August 13, 2008, Patentees through error and without deceptive intent, incorrectly calculated this value to be 518 days, rather than 488 days.

B. PTO Delays Under 35 U.S.C. §154(b)(1)(B)

“[I]f the issue of an original patent is delayed due to the failure of the United States Patent and Trademark Office to issue a patent within 3 years after the actual filing date of the application...not including (i) any time consumed by continued examination of the application requested by the application under section 132(b)...the term of the patent shall be extended 1 day for each day after the end of that 3-year period until the patent is issued.” 35 U.S.C. §154(b)(1)(B).

The instant application was filed on May 14, 2001. The three-year anniversary of the filing date is May 14, 2004. Patentees filed a Request for Continued Examination on September 20, 2005. Thus, the period of Office delay pursuant to 35 U.S.C. §154(b)(1)(B) is 494 days.

C. Total PTO Delays

The patent term adjustment due to PTO delays is the sum of PTO delays under 35 U.S.C. §154(b)(1)(A) and 35 U.S.C. §154(b)(1)(B). *See Wyeth v. Dudas*, 2008 WL 445642, 88 U.S.P.Q.2d 1538 (D.D.C 2008). However, “[t]o the extent that period of delay attributable to grounds specified in paragraph (1) overlap, the period of any adjustment granted under this subsection shall not exceed the actual number of days the issuance of the patent was delayed.” *Id.* at 2, citing 35 U.S.C. §154(b)(2)(A). Overlap occurs “only if they occur on the same calendar day or days.” *Id.* at 2-4.

With regard to the Office’s failure to respond to Patentees’ Response filed August 19, 2003 (Section II(A)(2) above), a portion of the time period wherein the Office did not issue an Office Action within 4 months “overlaps” with the Office’s delay as calculated under 35 U.S.C. §154(b)(1)(B). Patentees filed an Office Action Response on August 19, 2003. Under 35 U.S.C. §154(b)(1)(A)(ii), an Action was due December 19, 2003, *i.e.*, four months after Patentees’ Response. An Office Action was not mailed until April 20, 2005. However, since the three-year anniversary of the filing of the instant application was May 14, 2004, the period of Office delay under 35 U.S.C. §154(b)(1)(A)(ii) overlaps with that of the delay under 35 U.S.C. §154(b)(1)(B). The corrected Office delay under 35 U.S.C. §154(b)(1)(A)(ii) is therefore the period from December 19, 2003 to May 14, 2004, *i.e.*, 147 days.

Thus, the total patent term adjustment due to PTO delays is $142 + 147 + 494 = 783$ days.

D. Applicant Delays

As discussed above, the Office has improperly deducted 206 days. Thus, the patent term reduction accounting for Patentees' Delay is $377 - 206 = 171$.

E. Total Patent Term Adjustment


In view of the above, the total patent term adjustment is the difference between total PTO delays under 35 U.S.C. §154(b)(1)(A)-(B) and Applicant delays, *i.e.* $783 - 171 = \underline{612}$ days.

III. Conclusion

A fee of \$200.00 is believed due for the submission of this paper under 37 C.F.R. §1.18(e), 37 C.F.R. § 1.705(b)(1), and 37 C.F. R. §1.705(d), which will be paid via EFS Web. However, if any additional fees are due, the Director is authorized to charge them to Deposit Account No. 50-3013.

Date: December 12, 2008

Respectfully submitted,


Anthony M. Insogna

Reg. No.: 35,203

JONES DAY

12265 El Camino Real, Suite 200
San Diego, CA 92130
(858) 314-1200

Exhibit A

09/853,617	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER	12-10-2008::19:47:56
------------	--	----------------------

Patent Term Adjustments

Patent Term Adjustment (PTA) for Application Number: 09/853,617

Filing or 371(c) Date:	05-14-2001	USPTO Delay (PTO) Delay (days):	494
Issue Date of Patent:	10-14-2008	Three Years:	-
Pre-Issue Petitions (days):	+0	Applicant Delay (APPL) Delay (days):	377
Post-Issue Petitions (days):	+0	Total PTA (days):	117
USPTO Adjustment(days):	+0	Explanation Of Calculations	

Patent Term Adjustment History

Date	Contents Description	PTO(Days)	APPL(Days)
09-24-2008	PTA 36 Months	70	
10-14-2008	Patent Issue Date Used in PTA Calculation		
09-15-2008	Dispatch to FDC	↑	
09-02-2008	Application Is Considered Ready for Issue	↑	
08-29-2008	TC Return to Pubs	↑	
08-29-2008	Mail Miscellaneous Communication to Applicant	↑	
08-28-2008	Miscellaneous Communication to Applicant - No Action Count	↑	
08-13-2008	Issue Fee Payment Verified	↑	
08-13-2008	Issue Fee Payment Received	↑	
06-02-2008	Pubs Case Remand to TC	↑	
05-13-2008	Mail Notice of Allowance	↑	
05-12-2008	Document Verification	↑	
05-07-2008	Notice of Allowance Data Verification Completed	↑	
04-03-2008	Date Forwarded to Examiner	↑	
04-03-2008	Date Forwarded to Examiner	↑	
03-25-2008	Request for Continued Examination (RCE)		26
04-03-2008	DISPOSAL FOR A RCE/CPA/129 (express abandonment if CPA)		↑
03-25-2008	Request for Extension of Time - Granted		↑
03-25-2008	Workflow - Request for RCE - Begin		↑
11-28-2007	Mail Final Rejection (PTOL - 326)		↑
11-26-2007	Final Rejection		
09-10-2007	Miscellaneous Incoming Letter		
09-19-2007	Date Forwarded to Examiner		
09-07-2007	Response after Non-Final Action		
06-14-2007	Mail Non-Final Rejection		
06-11-2007	Non-Final Rejection		
03-20-2007	Date Forwarded to Examiner		
03-20-2007	Date Forwarded to Examiner		
03-08-2007	Request for Continued Examination (RCE)		
	DISPOSAL FOR A RCE/CPA/129 (express abandonment if		

03-20-2007	CPA)		
03-08-2007	Request for Extension of Time - Granted		
03-08-2007	Workflow - Request for RCE - Begin		
09-22-2006	Mail Advisory Action (PTOL - 303)		
09-18-2006	Advisory Action (PTOL-303)		
08-21-2006	Information Disclosure Statement considered		
06-29-2006	Information Disclosure Statement considered		
08-21-2006	Information Disclosure Statement (IDS) Filed		
08-21-2006	Information Disclosure Statement (IDS) Filed		
08-21-2006	Notice of Appeal Filed		62
08-28-2006	Date Forwarded to Examiner		↑
08-21-2006	Amendment after Final Rejection		↑
08-21-2006	Request for Extension of Time - Granted		↑
06-29-2006	Information Disclosure Statement (IDS) Filed		↑
06-29-2006	Information Disclosure Statement (IDS) Filed		↑
03-20-2006	Mail Final Rejection (PTOL - 326)		↑
03-16-2006	Final Rejection		
01-24-2006	Date Forwarded to Examiner		
01-17-2006	Response after Non-Final Action		
11-17-2005	Mail Non-Final Rejection		
11-14-2005	Non-Final Rejection		
09-29-2005	Date Forwarded to Examiner		
09-29-2005	Date Forwarded to Examiner		
09-20-2005	Request for Continued Examination (RCE)		62
09-29-2005	DISPOSAL FOR A RCE/CPA/129 (express abandonment if CPA)		↑
09-23-2005	IFW TSS Processing by Tech Center Complete		↑
09-20-2005	Workflow - Request for RCE - Begin		↑
07-26-2005	Mail Advisory Action (PTOL - 303)		↑
07-25-2005	Advisory Action (PTOL-303)		↑
07-05-2005	Date Forwarded to Examiner		↑
06-24-2005	Amendment after Final Rejection		↑
04-20-2005	Mail Final Rejection (PTOL - 326)	282	
04-18-2005	Final Rejection	↑	
02-10-2005	Date Forwarded to Examiner	↑	
03-12-2004	Response after Non-Final Action		206
05-19-2003	Mail Non-Final Rejection		↑
05-17-2003	Non-Final Rejection		
03-21-2003	Information Disclosure Statement (IDS) Filed		21
03-21-2003	Information Disclosure Statement (IDS) Filed		
03-11-2003	Date Forwarded to Examiner		↑
02-28-2003	Response to Election / Restriction Filed		↑

02-28-2003	Request for Extension of Time - Granted	
12-03-2002	Mail Restriction Requirement	142
12-02-2002	Requirement for Restriction / Election	↑
09-18-2002	Case Docketed to Examiner in GAU	↑
02-08-2002	Information Disclosure Statement (IDS) Filed	↑
02-08-2002	Information Disclosure Statement (IDS) Filed	↑
08-02-2002	Information Disclosure Statement (IDS) Filed	↑
08-02-2002	Information Disclosure Statement (IDS) Filed	↑
01-18-2002	Case Docketed to Examiner in GAU	↑
10-22-2001	Application Dispatched from OIPE	↑
10-22-2001	Application Is Now Complete	↑
07-11-2001	Notice Mailed--Application Incomplete--Filing Date Assigned	↑
07-11-2001	Correspondence Address Change	↑
05-18-2001	IFW Scan & PACR Auto Security Review	↑
05-14-2001	Initial Exam Team nn	↑

Close Window

Exhibit B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: ZELDIS et al.

Application No.: 09/853,617

Group Art Unit: 1623

Filed: May 14, 2001

Examiner: P. Lewis

For: COMPOSITIONS AND METHODS
FOR THE TREATMENT OF CANCER

Attorney Docket No.: 9516-022

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated May 19, 2003, Applicants submit the following amendments and remarks for entry into the record and consideration by the Examiner.

Amendments to the claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treating primary cancer which comprises administering to a patient in need of such treatment a therapeutically effective amount of a topoisomerase inhibitor, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.
2. (Original) A method of treating metastatic cancer which comprises administering to a patient in need of such treatment a therapeutically effective amount of a topoisomerase inhibitor, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, and a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof.
3. (Original) The method of claim 1 or 2 wherein the cancer is cancer of the head, neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, and brain.
4. (Original) The method of claim 3 wherein the cancer is colon or rectal cancer.
5. (Currently Amended) The method of claim 1 or 2 wherein the topoisomerase inhibitor is selected from the group consisting of camptothecin, ~~irinotecan~~ irinotecan, SN-38, topotecan, 9-aminocamptothecin, GG-211, DX-8951f, saintopin, UCE6, UCE1022, TAN-1518A, TAN-1518B, KT6006, KT6528, ED-110, NB-506, ED-110, NB-506, rebeccamycin, bulgarein, Hoescht dye 33342, Hoechst dye 33258, nitidine, fagaronine, epiberberine, coralyne, beta-lapachone, BC-4-1, IST-622, rubitecan, pyrazoloacridine, XR-5000, and pharmaceutically acceptable prodrugs, salts, solvates, clathrates, hydrates, and metabolites thereof.

6. (Original) The method of claim 1 wherein the topoisomerase inhibitor is not irinotecan.

7. (Original) The method of claim 5 wherein the topoisomerase inhibitor is irinotecan or SN-38.

8. (Original) The method of claim 7 wherein the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 1 to about 1000 mg/m², and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 1 to about 2000 mg.

9. (Original) The method of claim 8 wherein the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 25 to about 750 mg/m², and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 1000 mg.

10. (Original) The method of claim 9 wherein the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 50 to about 500 mg/m², and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 100 to about 750 mg.

11. (Original) The method of claim 10 wherein the irinotecan or SN-38, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 100 to about 350 mg/m², and the thalidomide, or pharmaceutically acceptable prodrug, salt, solvate, hydrate, or clathrate thereof, is administered in an amount of from about 200 to about 500 mg.

Claims 12-60. Canceled without prejudice.

Remarks

Claims 1-11 are now pending in this application. Claims 12-60 are canceled without prejudice to Applicants' rights to pursue the subject matter thereof in one or more divisional, continuation, or continuation-in-part applications. Claim 5 is amended to correct a typographical error. No new matter has been introduced.

The Rejection Under 35 U.S.C. § 112, ¶ 1, Should Be Withdrawn

On pages 3-5 of the Office Action, claims 1-11 are rejected under 35 U.S.C. § 112, ¶ 1, as allegedly failing to comply with the written description requirement. In sum, it is alleged that "the support in the specification is not adequate for the claim to the treatment of any primary or metastatic cancer comprising administering ... any topoisomerase inhibitor ..." Office Action, pages 3-4. Applicants respectfully traverse this rejection.

As the Examiner is well aware, the essential question in a written description requirement is whether "the description clearly allow[s] persons of ordinary skill in the art to recognize that he or she invented what is claimed." *In re Gosteli*, 872 F.2d 108, 1012 (Fed. Cir. 1989). While a question as to whether a specification provides an adequate written description may arise in the context of an original claim which is not described sufficiently, there is a strong presumption that an adequate written description is present in the specification as filed. *Manual of Patent Examining Procedure* ("MPEP") § 2163.03 (emphasis added). Accordingly, the examiner has the initial burden of presenting by a preponderance of the evidence why a person skilled in the art would not recognize in an applicant's disclosure a description of the invention defined by the claims. MPEP § 2163.04 (citing *In re Wertheim*, 521 F.2d 257, 263 (C.C.P.A. 1976)). A general allegation of "unpredictability in the art" is not a sufficient reason to support a rejection for lack of adequate written description. MPEP § 2163.04.

As the Examiner correctly recognized, the treatment of colorectal cancer by administering thalidomide and irinotecan is successfully demonstrated in this application at pages 31-32 of the specification. Detailed procedures of treating various cancers by administering thalidomide with other topoisomerase inhibitors are also described, for example, at pages 32-35 of the specification. Furthermore, it was well-known in the art at the time of this invention that various topoisomerase inhibitors are effective in treating various types of cancers, albeit with certain adverse

effects that could limit the amount or dose of the topoisomerase inhibitor that can be administered to patients. Therefore, Applicants respectfully submit that the claims 1-11 are adequately supported by the specification and the knowledge that was possessed by one of ordinary skill in the art. Applicants further submit that the Examiner has not met his initial burden of establishing *prima facie* case of lack of written description, as an allegation of “unpredictability in the art” is not sufficient to support such a rejection. MPEP § 2163.04.

For the foregoing reasons, Applicants respectfully request that the rejection under 35 U.S.C. § 112, ¶ 1, be withdrawn.

The Rejection Under 35 U.S.C. § 112, ¶ 2, Should Be Withdrawn

On pages 5-6 of the Office Action, claims 5 and 7-11 are rejected under 35 U.S.C. § 112, ¶ 2, as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter of the invention. Claims 5 and 7-11 are first rejected because alphanumeric terms, such as SN-38 and GG-211, allegedly have not been adequately defined in the specification or claims. Applicants respectfully traverse this rejection.

The alphanumeric terms used in the claims are the names of topoisomerase inhibitors that are commonly used and recognized by those of ordinary skill in the art. For example, SN-38 is chemically named as 7-ethyl-10-hydroxycamptothecin (*Cancer Chemotherapy and Biotherapy: Principles and Practice*, 3rd Ed. (2001) at page 581); GG-211, also known as GI 147211, is 7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin (Emerson *et al.*, *Cancer Res.* 55(3): 603-609 (1995)); UCE6 is 1,3,8,10,11-pentahydroxy-2-methyl-10-(2-oxo-4-hydroxypentyl)naphtahcene-5,12-dione (Fujii *et al.*, *J. Antibiot.* (Tokyo) 50(6): 490-495 (1997)); NB-506 is 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (Takenaga *et al.*, *Drug Metab. Dispos.* 27(2): 205-212 (1999)); IST-622 is 6-O-(3-ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin (Tashiro *et al.*, *Cancer Chemother. Pharmacol.* 34(4): 287-292 (1994)); and XR-5000, also known as DACA, is N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (*Cancer Chemotherapy and Biotherapy: Principles and Practice*, 3rd Ed. (2001) at page 579). The other alphanumeric terms recited by the claims also have unambiguous meanings known by those of ordinary skill in the art. For this reason, Applicants respectfully

submit that claims 5 and 7-11 are not indefinite. MPEP § 2173.05(t) (citing *Martin v. Johnson*, 454 F.2d 746 (C.C.P.A. 1972) (“Chemical compounds may be claimed by a name that adequately describes the material to one skilled in the art.”)).

Claims 8-11 are next rejected as allegedly indefinite because the amount of irinotecan or SN-38 recited in the claims are expressed in a concentration range. The concentration unit used in the claims (*i.e.*, mg/m²) means the amount in mg used per m² of the patient’s body area. This unit is widely used in the pharmaceutical industry, especially in connection with the treatment of cancer using parenterally delivered drugs, as it is important to determine the appropriate amount to be used according to the size of the patient in treating cancers. *See, e.g., Physician’s Desk Reference*, 54th Ed., page 2412-2418 (2000), which was submitted as Document BK in the Information Disclosure Statement filed February 8, 2002. For this reason, Applicants respectfully submit that the pending claims are not indefinite, and the rejection under 35 U.S.C. § 112, ¶ 2, should be withdrawn.

The Rejection Under 35 U.S.C. § 103 Should Be Withdrawn

On pages 6-9 of the Office Action, claims 1-11 are rejected as allegedly obvious over Marx *et al.*, *Proc. Am. Soc. Clin. Oncology* 18: 454a (1999) (“Marx”), in view of Pitot *et al.*, *Journal of Clinical Oncology* 15(8): 2910-2919 (1997) (“Pitot”) and U.S. Patent No. 5,622,959 to Priel *et al.* (“the ‘959 patent”). In particular, it is alleged that because Marx discloses an antiangiogenic effect of thalidomide and Pitot and the ‘959 patent disclose antitumor activities of CPT-11 and CPT, respectively, the claimed invention is obvious. Applicants respectfully traverse this rejection for the following reasons.

As the Examiner is aware, three basic criteria must be met in order to establish a case of *prima facie* obviousness: first, there must have been a motivation to combine the cited references at the time the invention was made; second, the alleged prior art must disclose or suggest all of the limitations of the claims alleged to be obvious; and third, there must have been at the time of the invention a reasonable expectation of success. MPEP §2142. Furthermore, hindsight cannot be used to reject a claim as obvious. MPEP § 2141.01. Consequently, when determining whether or not a claimed invention is obvious, one must cast her “mind back to the time of invention, to consider the thinking of one of ordinary skill in the art, guided only by the prior art references and the then-accepted wisdom in the field.” *In re*

Dembiczak, 175 F.3d 994, 999 (Fed.Cir. 1999) (reversing a determination that several claims were obvious over a combination of references that disclosed all of their limitations, but which did not provide a motivation to combine those limitations). Applicants respectfully submit that these criteria are not met by the combination of Marx, Pitot, and the '959 patent.

The Examiner, citing *Ex parte Quadranti*, 25 U.S.P.Q.2d 1071 (Bd. Pat. Appl. & Inter. 1992), alleges that the co-administration of two components, each of which is recognized as having anticancer activity, would have been obvious "in the absence of some proof of a secondary nature or some specific limitations which would tip the scale of patentability in favor of the claimed invention." Office Action at page 9. Applicants respectfully submit that such proof can be found in the application as filed.

As indicated in the specification, this invention is based, in part, on the ability of thalidomide to: (1) treat cancer; (2) improve the efficacy of other chemotherapeutic or radiation therapies for cancer; or (3) lessen the severity of certain dose-limiting toxicities of other anticancer drugs. The specification, page 11, line 38 - page 12, line 3. Thus, when thalidomide is co-administered with irinotecan to patients with metastatic colorectal cancer, a remarkable absence of gastrointestinal toxicity typically associated with irinotecan is observed. *Id.* at page 31, line 24 - page 32, line 21. None of the cited references disclose or even suggest this remarkable effect.

In addition, thalidomide was not an approved anticancer agent at the time of this invention, while numerous other agents known to be effective in treating cancer were. As such, these references would not have provided the necessary motivation to combine thalidomide with a topoisomerase inhibitor because one of ordinary skill in the art would have been likely to combine other known anticancer agents first with topoisomerase inhibitors. Thus, Applicants respectfully submit that the rejection under 35 U.S.C. § 103 could only be made with the aid of an impermissible hindsight. *Dembiczak*, 175 F.3d at 999. Similarly, the cited art certainly would not have provided any suggestion that the claimed invention would be successful. For these reasons, Applicants respectfully request that the rejection under 35 U.S.C. § 103 be withdrawn.

Conclusion

For the foregoing reasons, Applicants respectfully submit that claims 1-11 are allowable. No fee is believed due for this submission. However, should any fees be due for this submission or to avoid abandonment of the application, please charge such fees to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Date August 17, 2003

Respectfully submitted,

Max Bachrach 45,479
Max Bachrach (Reg. No.)

PENNIE & EDMONDS LLP

1667 K Street, N.W.

Washington, DC 20006

(202) 496-4400

For: Anthony M. Insogna (Reg. No. 35,203)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, NY 10036

(212) 790-9090

Exhibit C

09/853,617

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

12-10-
2008::19:50:36

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click PDF.

Bibliographic Data

Mail Room Date	Document Code	Document Description	Document Category	Page Count
09-24-2008	ISSUE.NTF	Issue Notification	PROSECUTION	1
08-29-2008	M327	Miscellaneous Communication to Applicant - No Action Count	PROSECUTION	2
08-29-2008	1449	List of References cited by applicant and considered by examiner	PROSECUTION	3
08-29-2008	1449	List of References cited by applicant and considered by examiner	PROSECUTION	3
08-13-2008	IFEE	Issue Fee Payment (PTO-85B)	PROSECUTION	1
08-13-2008	PET.OP	Petition for review by the Office of Petitions.	PROSECUTION	19
08-13-2008	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	2
08-13-2008	N417	EFS Acknowledgment Receipt	PROSECUTION	2
06-02-2008	BIB	Bibliographic Data Sheet	PROSECUTION	1
05-13-2008	NOA	Notice of Allowance and Fees Due (PTOL-85)	PROSECUTION	4
05-13-2008	BIB	Bibliographic Data Sheet	PROSECUTION	1
05-13-2008	FWCLM	Index of Claims	PROSECUTION	2
05-13-2008	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	PROSECUTION	1
05-13-2008	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
03-25-2008	RCEX	Request for Continued Examination (RCE)	PROSECUTION	1
03-25-2008	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	2
03-25-2008	N417	EFS Acknowledgment Receipt	PROSECUTION	2
03-25-2008	AMSB	Amendment Submitted/Entered with Filing of CPA/RCE	PROSECUTION	1
03-25-2008	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	38
03-25-2008	XT/	Extension of Time	PROSECUTION	1
11-28-2007	CTFR	Final Rejection	PROSECUTION	8
11-28-2007	BIB	Bibliographic Data Sheet	PROSECUTION	1
11-28-2007	FWCLM	Index of Claims	PROSECUTION	1
11-28-2007	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
11-20-2007	SRNT	Examiner's search strategy and results	PROSECUTION	1
09-10-2007	LET.	Miscellaneous Incoming Letter	PROSECUTION	2
09-10-2007	NPL	NPL Documents	PRIOR ART	14
09-10-2007	NPL	NPL Documents	PRIOR ART	3
09-07-2007	A...	Amendment/Req. Reconsideration-After Non-Final Reject	PROSECUTION	1
09-07-2007	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	5
06-14-2007	CTNF	Non-Final Rejection	PROSECUTION	7
06-14-2007	892	List of references cited by examiner	PRIOR ART	1
06-14-2007	NPL	NPL Documents	PRIOR ART	11
06-14-2007	BIB	Bibliographic Data Sheet	PROSECUTION	1
06-14-2007	FWCLM	Index of Claims	PROSECUTION	1
06-14-2007	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1

05-30-2007	SRNT	Examiner's search strategy and results	PROSECUTION	1
03-22-2007	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
03-08-2007	AMSB	Amendment Submitted/Entered with Filing of CPA/RCE	PROSECUTION	1
03-08-2007	CLM	Claims	PROSECUTION	2
03-08-2007	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	3
03-08-2007	XT/	Extension of Time	PROSECUTION	1
03-08-2007	RCEX	Request for Continued Examination (RCE)	PROSECUTION	1
03-08-2007	136A	Authorization for Extension of Time all replies	PROSECUTION	1
09-22-2006	CTAV	Advisory Action (PTOL-303)	PROSECUTION	3
09-22-2006	BIB	Bibliographic Data Sheet	PROSECUTION	1
08-21-2006	N/AP	Notice of Appeal Filed	PROSECUTION	1
08-21-2006	XT/	Extension of Time	PROSECUTION	1
08-21-2006	A.NE	Amendment After Final	PROSECUTION	1
08-21-2006	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	29
08-21-2006	IDS	Information Disclosure Statement (IDS) Filed (SB/08)	PROSECUTION	3
08-21-2006	NPL	NPL Documents	PRIOR ART	1
08-21-2006	NPL	NPL Documents	PRIOR ART	11
06-29-2006	IDS	Information Disclosure Statement (IDS) Filed (SB/08)	PROSECUTION	3
06-29-2006	NPL	NPL Documents	PRIOR ART	2
06-29-2006	NPL	NPL Documents	PRIOR ART	8
06-29-2006	NPL	NPL Documents	PRIOR ART	19
03-20-2006	CTFR	Final Rejection	PROSECUTION	10
03-20-2006	892	List of references cited by examiner	PRIOR ART	1
03-20-2006	FWCLM	Index of Claims	PROSECUTION	1
03-20-2006	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
03-20-2006	BIB	Bibliographic Data Sheet	PROSECUTION	2
03-15-2006	SRNT	Examiner's search strategy and results	PROSECUTION	2
01-25-2006	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
01-25-2006	WCLM	Claims Worksheet (PTO-2022)	PROSECUTION	1
01-17-2006	A...	Amendment/Req. Reconsideration-After Non-Final Reject	PROSECUTION	1
01-17-2006	CLM	Claims	PROSECUTION	3
01-17-2006	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	5
11-17-2005	CTNF	Non-Final Rejection	PROSECUTION	7
11-17-2005	FWCLM	Index of Claims	PROSECUTION	1
11-17-2005	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
11-17-2005	BIB	Bibliographic Data Sheet	PROSECUTION	2
11-17-2005	ANE.I	Amendment After Final or under 37CFR 1.312, initialed by the examiner.	PROSECUTION	1
11-01-2005	SRNT	Examiner's search strategy and results	PROSECUTION	2
09-20-2005	AMSB	Amendment Submitted/Entered with Filing of CPA/RCE	PROSECUTION	1
09-20-2005	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	4
09-20-2005	RCEX	Request for Continued Examination (RCE)	PROSECUTION	1
09-20-2005	XT/	Extension of Time	PROSECUTION	1
07-26-2005	CTAV	Advisory Action (PTOL-303)	PROSECUTION	3

06-24-2005	A.NE	Amendment After Final	PROSECUTION	1
06-24-2005	CLM	Claims	PROSECUTION	3
06-24-2005	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	8
06-24-2005	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
06-24-2005	WCLM	Claims Worksheet (PTO-2022)	PROSECUTION	1
04-20-2005	CTFR	Final Rejection	PROSECUTION	7
04-20-2005	FWCLM	Index of Claims	PROSECUTION	1
04-20-2005	BIB	Bibliographic Data Sheet	PROSECUTION	2
04-20-2005	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
04-08-2005	SRNT	Examiner's search strategy and results	PROSECUTION	2
04-07-2005	SRNT	Examiner's search strategy and results	PROSECUTION	4
03-14-2004	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
03-14-2004	WCLM	Claims Worksheet (PTO-2022)	PROSECUTION	1
03-12-2004	A...	Amendment/Req. Reconsideration-After Non-Final Reject	PROSECUTION	1
03-12-2004	CLM	Claims	PROSECUTION	2
03-12-2004	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	5
03-12-2004	TRTC	Transmittal to TC	PROSECUTION	1
08-19-2003	LET.	Miscellaneous Incoming Letter	PROSECUTION	1
05-19-2003	CTNF	Non-Final Rejection	PROSECUTION	11
05-19-2003	892	List of references cited by examiner	PRIOR ART	1
05-19-2003	NPL	NPL Documents	PRIOR ART	2
05-19-2003	NPL	NPL Documents	PRIOR ART	10
05-19-2003	1449	List of References cited by applicant and considered by examiner	PRIOR ART	4
05-07-2003	SRNT	Examiner's search strategy and results	PROSECUTION	2
05-06-2003	SRNT	Examiner's search strategy and results	PROSECUTION	13
03-21-2003	IDS	Information Disclosure Statement (IDS) Filed (SB/08)	PROSECUTION	1
03-21-2003	NPL	NPL Documents	PRIOR ART	9
02-28-2003	A...	Amendment/Req. Reconsideration-After Non-Final Reject	PROSECUTION	1
02-28-2003	REM	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	1
02-28-2003	XT/	Extension of Time	PROSECUTION	1
12-03-2002	CTRS	Requirement for Restriction/Election	PROSECUTION	6
08-02-2002	IDS	Information Disclosure Statement (IDS) Filed (SB/08)	PRIOR ART	1
08-02-2002	NPL	NPL Documents	PRIOR ART	2
08-02-2002	NPL	NPL Documents	PRIOR ART	7
02-08-2002	IDS	Information Disclosure Statement (IDS) Filed (SB/08)	PROSECUTION	2
02-08-2002	FOR	Foreign Reference	PRIOR ART	50
02-08-2002	NPL	NPL Documents	PRIOR ART	17
02-08-2002	NPL	NPL Documents	PRIOR ART	10
02-08-2002	NPL	NPL Documents	PRIOR ART	3
02-08-2002	NPL	NPL Documents	PRIOR ART	7
02-08-2002	NPL	NPL Documents	PRIOR ART	3
02-08-2002	NPL	NPL Documents	PRIOR ART	2
02-08-2002	NPL	NPL Documents	PRIOR ART	7
02-08-2002	NPL	NPL Documents	PRIOR ART	4
02-08-2002	NPL	NPL Documents	PRIOR ART	5

02-08-2002	NPL	NPL Documents	PRIOR ART	3
02-08-2002	NPL	NPL Documents	PRIOR ART	1
02-08-2002	NPL	NPL Documents	PRIOR ART	4
02-08-2002	NPL	NPL Documents	PRIOR ART	8
02-08-2002	NPL	NPL Documents	PRIOR ART	5
02-08-2002	NPL	NPL Documents	PRIOR ART	5
02-08-2002	NPL	NPL Documents	PRIOR ART	10
02-08-2002	NPL	NPL Documents	PRIOR ART	79
02-08-2002	NPL	NPL Documents	PRIOR ART	14
02-08-2002	NPL	NPL Documents	PRIOR ART	2
02-08-2002	NPL	NPL Documents	PRIOR ART	9
02-08-2002	NPL	NPL Documents	PRIOR ART	2
02-08-2002	NPL	NPL Documents	PRIOR ART	5
02-08-2002	NPL	NPL Documents	PRIOR ART	5
02-08-2002	NPL	NPL Documents	PRIOR ART	7
02-08-2002	NPL	NPL Documents	PRIOR ART	9
02-08-2002	NPL	NPL Documents	PRIOR ART	11
02-08-2002	NPL	NPL Documents	PRIOR ART	7
02-08-2002	NPL	NPL Documents	PRIOR ART	8
02-08-2002	NPL	NPL Documents	PRIOR ART	9
02-08-2002	NPL	NPL Documents	PRIOR ART	20
02-08-2002	NPL	NPL Documents	PRIOR ART	3
02-08-2002	NPL	NPL Documents	PRIOR ART	11
02-08-2002	NPL	NPL Documents	PRIOR ART	11
02-08-2002	NPL	NPL Documents	PRIOR ART	9
02-08-2002	NPL	NPL Documents	PRIOR ART	9
02-08-2002	NPL	NPL Documents	PRIOR ART	4
02-08-2002	NPL	NPL Documents	PRIOR ART	11
02-08-2002	NPL	NPL Documents	PRIOR ART	5
02-08-2002	NPL	NPL Documents	PRIOR ART	2
02-08-2002	NPL	NPL Documents	PRIOR ART	13
09-21-2001	XT/	Extension of Time	PROSECUTION	1
09-21-2001	PA..	Power of Attorney	PROSECUTION	2
09-21-2001	OATH	Oath or Declaration filed	PROSECUTION	2
09-21-2001	LET.	Miscellaneous Incoming Letter	PROSECUTION	2
07-11-2001	CTMS	Miscellaneous Action with SSP	PROSECUTION	1
05-14-2001	TRNA	Transmittal of New Application	AS FILED	2
05-14-2001	SPEC	Specification	AS FILED	35
05-14-2001	CLM	Claims	AS FILED	8
05-14-2001	ABST	Abstract	AS FILED	1
05-14-2001	OATH	Oath or Declaration filed	AS FILED	4
05-14-2001	IIFW	Issue Information including classification, examiner, name, claim, renumbering, etc.	PROSECUTION	1
05-14-2001	SRFW	Search information including classification, databases and other search related notes	PROSECUTION	1
05-14-2001	FWCLM	Index of Claims	PROSECUTION	1
05-14-2001	TRNA	Transmittal of New Application	PROSECUTION	2
05-14-2001	SPEC	Specification	PROSECUTION	35
05-14-2001	CLM	Claims	PROSECUTION	8
05-14-2001	ABST	Abstract	PROSECUTION	1
05-14-2001	OATH	Oath or Declaration filed	PROSECUTION	4
05-14-2001	BIB	Bibliographic Data Sheet	PROSECUTION	2
05-14-2001	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1
05-14-2001	WFEE	Fee Worksheet (PTO-06)	PROSECUTION	1

05-14-2001	WCLM	Claims Worksheet (PTO-2022)	PROSECUTION	1
------------	------	-----------------------------	-------------	---

Close Window

Exhibit D

Ex
Det
Ser
Inv
For

HAND CARRY
Date Mailed August 19, 2003
Serial No. 09/853,617 Filed May 14, 2001
Inventor ZELDIS et al.
For COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

- () ☐ Affidavit/Declaration
() ☒ Amendment
() ☐ Application pages
() ☐ Claims Drawing Sheet
() ☐ Appeal, Notice of
() ☐ Assignment
() ☐ Brief (in Triplicate)
() ☐ Declaration of Inventors
() ☐ Design Application
() ☐ Disclaimer
() ☐ Disclaimers
() ☐ Disclosure Statement ☐ Form TO-1440
() ☐ Chw.ref. ☐ w/o ref.
() ☐ Drawings, Formal
() Sheets Figures

Other: _____
File no.: 9516-022-999

- ☐ Fee Address Indication Form
☐ Fee Calculation
☐ Issue Fee Transmittal
☐ Letter
☐ Oral Hearing Request/Confirm
☐ Petition to Extend Time
☐ Petition Under 37 C.F.R.
☐ Power of Attorney
☐ Associate 0 w/Revocation
☐ Sequence Listing w/ Computer
Readable and Paper Copy
☐ Small Entity Statement
☐ Transmittal Letter DO/EQ/US
By Deposit Account No. 16-1150

Other: _____

Sender: _____

File No. _____

Exhibit E



Facsimile Transmission

51 LOUISIANA AVENUE, N.W. • WASHINGTON, D.C. 20001-2113 • (202) 879-3939
Facsimile: (202) 626-1700
mbachrach@jonesday.com

March 12, 2004

Please hand deliver the following facsimile to:

Name/Company:	Facsimile Number:	Telephone Number:
Examiner Patrick Lewis	571-273-0655	

☐ Copies distributed _____

From: Max Bachrach

Direct Telephone No.: (202) 496-4456

Direct Facsimile No.: (202) 835-4444

JP No.: 006669

CAM No.:

Send copies to:

Number of pages (including this page): 10

Re: U.S. Patent Application No. 09/853,617

NOTICE: This communication is intended to be confidential to the person to whom it is addressed, and it is subject to copyright protection. If you are not the intended recipient or the agent of the intended recipient or if you are unable to deliver this communication to the intended recipient, please do not read, copy or use this communication or show it to any other person, but notify the sender immediately by telephone at the direct telephone number noted above.

Message: Attached is a copy of the postcard receipt and Response.

Please call us immediately if the facsimile you receive is incomplete or illegible. Please ask for the facsimile operator.

DocID

ATLANTA • BEIJING • BRUSSELS • CHICAGO • CLEVELAND • COLUMBUS • DALLAS • FRANKFURT • HONG KONG • HOUSTON
IRVINE • LONDON • LOS ANGELES • MADRID • MENLO PARK • MILAN • MUMBAI • MUNICH • NEW DELHI • NEW YORK
PARIS • PITTSBURGH • SAN FRANCISCO • SHANGHAI • SINGAPORE • SYDNEY • TAIPEI • TOKYO • WASHINGTON

PAGE 1/10 • RCVD AT 3/12/2004 3:12:09 PM [Eastern Standard Time] • SVR:USPTO-EFAXF-1/24 • DNS:2730655 • CSID: • DURATION (mm-ss):02:52